IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)

Key facts

Sponsor

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Principal Investigator

zhijian xiao, PHD

Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Intervention

IMM01(drug)

Enrollment

170 enrolled

Eligibility

18 years · All sexes

Timeline

2024 – 2029

Study locations (30)

• Anhui Provincial Hospital, Hefei, Anhui, China
• China-Japan Friendship Hospita, Beijing, Beijing Municipality, China
• The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
• First Hospital of Lanzhou University, Lanzhou, Gansu, China
• The First Affiliated Hospital of Guangxi Medical University, Nanning, Gaungxi, China
• Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
• Shenzhen Second People's Hospital, Shenzhen, Guangdong, China
• Zhujiang Hospital of Southern Medical University, Zhujiang, Guangdong, China
• Guangdong Provincial People's Hospital, Guangzhou, Guangzhou, China
• Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
• Affiliated Hospital of Hebei University, Shijiazhuang, Hebei, China
• The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
• Harbin First Hospital, Harbin, Heilongjiang, China
• First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
• Henan Cancer Hospital, Zhengzhou, Henan, China
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Chronic myelomonocytic leukemia

Additional recruiting or active studies for the same condition.

• RECRUITINGEARLY PHASE1NCT07071155
  Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia
  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• RECRUITINGNCT07512882
  Cohort of Patients With Chronic Myelomonocytic Leukemia
  Gustave Roussy, Cancer Campus, Grand Paris
• RECRUITINGPHASE2NCT06815003
  Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
  City of Hope Medical Center
• RECRUITINGPHASE2NCT06597734
  A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
  M.D. Anderson Cancer Center
• RECRUITINGPHASE1NCT06543381
  Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
  City of Hope Medical Center
• RECRUITINGPHASE1, PHASE2NCT06159491
  Pacritinib in CMML
  Douglas Tremblay
• RECRUITINGPHASE1NCT06218628
  Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
  Fox Chase Cancer Center
• RECRUITINGPHASE1NCT06071624
  Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.
  Huda Salman

See all trials for Chronic myelomonocytic leukemia →